BTIG analyst Ryan Zimmerman maintained a Buy rating on Glaukos (GKOS – Research Report) today and set a price target of $112.00. The company’s shares closed yesterday at $98.91.
Zimmerman covers the Healthcare sector, focusing on stocks such as Vericel, Intuitive Surgical, and Glaukos. According to TipRanks, Zimmerman has an average return of 9.6% and a 47.47% success rate on recommended stocks.
Glaukos has an analyst consensus of Strong Buy, with a price target consensus of $110.89, implying a 12.11% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $113.00 price target.
The company has a one-year high of $103.66 and a one-year low of $45.47. Currently, Glaukos has an average volume of 509.4K.
Based on the recent corporate insider activity of 88 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GKOS in relation to earlier this year. Last month, David Hoffmeister, a Director at GKOS bought 10,000.00 shares for a total of $72,700.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Glaukos (GKOS) Company Description:
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
